Shengshuo Yan

Shengshuo Yan

Auto-generated profile, based on publicly available information

Shengshuo Yan

Zhejiang‐California International NanoSystems Institute Hangzhou China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2026 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
RMRongwei Mao
Rongwei Mao
SYShengshuo Yan
Shengshuo Yan
ASAditi A. Sharma
Aditi A. Sharma
TSTony Shum
Tony Shum
YZYang Zhang
Yang Zhang
Background: Noninvasive radiofrequency (RF) therapy has emerged as a prominent approach for facial rejuvenation due to its ability to stimulate collagen remodeling without epidermal ablation. However, conventional RF systems often rely on high thermal output, posing risks of heat‐induced dermal damage. Objective: This study aimed to evaluate the safety and efficacy of a novel micro‐RF device (nebulyft), utilizing a high‐density 321‐electrode MEMS array designed to deliver high precision low‐power phase‐controlled RF energy for facial wrinkle reduction and improved skin texture. Methods: In this prospective, open‐label clinical trial, 42 participants from California, USA (age 29–62, Fitzpatrick skin types II–IV) completed a 4‐week treatment protocol using the nebulyft device. Each subject underwent one supervised clinic‐based session, followed by at‐home treatments (16 min per session, ≥ 5 sessions per week). Efficacy was assessed using the Fitzpatrick Wrinkle Severity Scale (FWSS) by three blinded board‐certified dermatologists, and subject satisfaction was recorded via a 4‐point Likert scale. Results: At one‐month post‐treatment visit, 90.5% of participants in the primary FAS (38/42) met the ≥ 1‐point FWSS responder criterion; the supportive PPS result was 92.7% (38/41), as determined by at least two blinded evaluators (FAS exact one‐sided p = 0.0015 vs. the prespecified 70% performance goal). The mean subject satisfaction score was 15.76 ± 0.54 out of 16. No pain was reported by any participant during treatment sessions. No adverse events, discomfort, or device malfunctions were reported.